Products

BioTraceIO Vision
Techsomed Medical Technologies
Oncology AI
BioTraceIO Vision is an AI-powered software by Techsomed Medical Technologies that enhances image-guided ablation therapy through personalized treatment planning, real-time visualization, and advanced assessment tools, integrating with standard medical imaging for improved precision and efficiency.

See all 1 product →

About Techsomed Medical Technologies

TechsoMed Medical Technologies is a medical imaging software company dedicated to significantly enhancing clinical outcomes in Oncology, Cardiology, and Pain Management. Their flagship product, BioTraceIO 360, is an AI-powered, real-time thermal ablation management system. This innovative platform seamlessly integrates with standard commercial ultrasound imaging systems, and can also leverage CT and MRI data, to provide physicians with real-time visualization and comprehensive analysis of tissue viability during thermal ablation procedures. The core objective of their technology is to optimize procedural accuracy and efficacy through patient-specific visualization, continuous monitoring, and predictive outcomes, effectively transforming traditional guesswork into data-driven guidance for interventionalists.

For physicians, BioTraceIO 360 offers critical intra-procedural feedback during minimally invasive thermal ablation treatments, which are widely applied for tumor destruction (notably in the liver and kidney), management of heart arrhythmias, and chronic pain management through radiofrequency neurotomy. The system employs advanced AI algorithms to analyze echogenicity variations and microvascular changes, generating an immediate ablation damage map that accurately estimates the extent of thermal damage 24 hours post-treatment, correlating strongly with post-procedural CECT scans. This capability enables immediate procedural adjustments, leading to improved treatment precision, minimized damage to healthy tissue, maximized target tissue ablation, and ultimately, enhanced patient outcomes with reduced recurrence rates. TechsoMed has secured FDA 510(k) clearance for its VisAble.IO software for planning liver ablation procedures and confirming ablation zones, and De Novo clearance for BioTraceIO for tissue response prediction in liver tumor ablation.

Focus Areas

AI-powered image-guided ablation therapy real-time tissue response monitoring oncology (liver kidney tumors) cardiology (heart arrhythmia) pain management

Business Intelligence

Key InvestorsJohnson & Johnson Innovation – JJDC Inc., Axil Capital, SCREEN Holdings, AMIT-Alfred Mann Institute at Technion, NextLeap Ventures, 4BIO Capital, Astellas Venture Management, Remiges Ventures, Cobro Ventures, Magna Capital Partners, Radianx Capital, Yongjin Capital
PartnershipsMedtronic, GE HealthCare, Fraunhofer MEVIS, Juntendo University
AcquisitionsJoint Venture with TechsoMed Japan K.K.
TechnologyBioTrace™ platform (BioTraceIO, BioTraceIO360, VisAble.IO), AI-powered, hardware-agnostic, integrates with standard commercial ultrasound devices, unifies CT, MRI, and ultrasound data, generative AI
FDA Clearances2+ cleared products (estimated)

What Physicians Need to Know

AI-Powered Image-Guided Ablation Therapy
Techsomed specializes in AI-powered image-guided ablation therapy, primarily through its BioTraceu2122 platform, which provides real-time visualization and analysis of tissue viability during thermal ablation procedures.
Real-Time Tissue Response Monitoring
The BioTraceu2122 platform offers live tissue damage mapping during ablation, enabling immediate procedural adjustments and predictive insights on post-ablation tissue damage, a capability previously unavailable.
Oncology (Liver & Kidney Tumors)
Their BioTraceIOu2122 and BioTraceIO360u2122 platforms are FDA-cleared for liver tumor ablation and have expanded to include kidney ablation, with plans to extend to other soft tissue tumors like thyroid, prostate, and breast cancer.
Cardiology (Heart Arrhythmia)
The technology supports applications in cardiology for the treatment of heart arrhythmia.
Pain Management
Techsomed's technology also extends to applications in pain management.
Physician Tip

For physicians, Techsomed's BioTraceu2122 platform offers unprecedented real-time feedback and predictive modeling, transforming ablation procedures from guesswork into precise, data-driven guidance. Leverage its hardware-agnostic nature to integrate seamlessly with your existing ultrasound, CT, and MRI systems. Utilize the comprehensive planning, intra-procedural guidance, and post-procedure assessment tools to optimize ablation margins, minimize damage to healthy tissue, and confirm treatment success, thereby aiming for higher efficacy and lower recurrence rates across oncology (liver, kidney), cardiology, and pain management applications. The system's ability to provide patient-specific treatment planning and predictive insights can significantly enhance clinical decision-making and improve patient outcomes.

Techsomed's BioTraceu2122 platform is designed for broad compatibility, being hardware-agnostic and integrating with standard commercial ultrasound, CT, and MRI imaging systems. This allows for seamless incorporation into existing clinical workflows without requiring specialized imaging hardware. Furthermore, Techsomed has established collaborations, such as with Medtronic, to combine their BioTraceIO360u2122 software with specific ablation devices like the Medtronic Emprintu2122 microwave ablation system, indicating potential for direct, optimized integrations with various ablation technologies. The platform unifies planning, execution, and monitoring, suggesting robust integration points across the entire image-guided therapy continuum.

Products by Techsomed Medical Technologies

1 product in the directory

BioTraceIO Vision
Techsomed Medical Technologies
Oncology AI
BioTraceIO Vision is an AI-powered software by Techsomed Medical Technologies that enhances image-guided ablation therapy through personalized treatment planning, real-time visualization, and advanced assessment tools, integrating with standard medical imaging for improved precision and efficiency.

Reviews & Opinions

No web reviews on file yet for Techsomed Medical Technologies. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Techsomed Medical Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Techsomed Medical Technologies →

View all on YouTube

Press & Coverage

BioSpace
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Medical Technologies LTD announced that its BioTraceIO, an ultrasound-based liver ablation software for tissue response prediction, has received De Novo clearance from the FDA. This marks a significant step towards commercialization in the USA, offering physicians enhanced precision in ablation therapy.
2024-01
Healthcare IT News
FDA grants real-time liver ablation AI clearance
The U.S. Food and Drug Administration granted De Novo clearance to Techsomed's BioTraceIO, an AI-powered ablation treatment platform that analyzes ultrasound images to track tissue response during liver ablation treatment. This clearance is considered a game-changer for image-guided ablation therapy.
2024-01
American Technion Society
Liver Tumor Treatment Gets a High-Tech Upgrade
Techsomed Medical Technologies, an Israeli company, received FDA De Novo clearance for its BioTraceIO software, which predicts tissue response to ablation therapy and provides real-time visuals during liver tumor removal. The company's founder and CEO, Yossi Abu, and Chief Strategy Officer Eran Naveh are Technion alumni.
2024-01
PLOS ONE
Retrospective evaluation of a novel ultrasound-based imaging analysis software for predicting radiofrequency ablation areas
This peer-reviewed article evaluates BioTrace, a novel software from Techsomed Medical Technologies, designed for real-time monitoring of thermal ablation tissue damage during image-guided radiofrequency ablation for hepatocellular carcinoma. The study found that BioTrace effectively generates an ablation damage prediction map, accurately predicting the ablation zone.
2025-01
Synapse
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
Techsomed announced FDA clearance for its ablation treatment planning and confirmation software. This software assists physicians in planning ablation procedures, including identifying targets and virtual needle placement, and confirming ablation zones.
2023-09
PR Newswire
Techsomed and Medtronic to Collaborate on Image Guided Ablation Therapy
Techsomed and Medtronic are collaborating on image-guided ablation therapy. This partnership aims to further develop and commercialize Techsomed's BioTraceu2122 system, which provides real-time predictive imaging for thermal ablation procedures.
2025-10
CTech
Cancer Treatment Monitoring Startup Techsomed Raises $2.6 Million
Medtech startup Techsomed Medical Technologies Ltd. raised $2.6 million in a funding round led by Johnson & Johnson Innovationu2013JJDC Inc. The funding will be used to obtain regulatory approval in the U.S., European Union, and Japan for its image analysis system that tracks tissue response to thermal ablation.
2019-05
PR Newswire
Techsomed Secures $2.6M for Groundbreaking Real-time Predictive Imaging System for Thermal Ablation
Techsomed secured $2.6 million in a financing round led by Johnson & Johnson Innovation u2013 JJDC, Inc., to further develop its BioTraceu2122 system. This system is the world's first image analysis system for predicting post-treatment ablation morphology in real-time, aiming for FDA, PMDA, and CE regulatory approval.
2019-05

Frequently Asked Questions

Techsomed specializes in AI-powered image-guided ablation therapy through its BioTraceu2122 platform, which integrates with standard ultrasound systems. This technology provides real-time visualization and analysis of tissue viability during thermal ablation procedures, aiming to enhance precision and improve patient outcomes.
The BioTrace platform is primarily cleared by the FDA for percutaneous ablation of soft tissue in the liver and kidney, addressing tumors in these organs. Techsomed also aims to expand its applications to other interventional oncology workflows, including thyroid, prostate, and breast cancer, as well as cardiology (heart arrhythmia) and pain management.
Techsomed's BioTraceIO Precision software utilizes advanced AI algorithms to analyze real-time ultrasound images, tracking the targeted tissue's biological signature as it responds to heat. This allows for immediate visualization and prediction of the post-ablation tissue damage, transforming guesswork into precise, feedback-dependent treatments.
Techsomed's BioTraceIO Vision and BioTraceIO Precision software have received FDA clearances, including De Novo clearance for BioTraceIO for liver tumor ablation. BioTraceIO Vision provides personalized treatment planning, while BioTraceIO Precision offers predictive insights on post-ablation tissue damage using real-time ultrasound data.
Techsomed has formed significant partnerships, including a collaboration with Medtronic to combine their BioTraceIO360 software with Medtronic's Emprint microwave ablation system. They also work with Fraunhofer MEVIS for R&D and have received funding from investors like Johnson & Johnson Innovation, indicating strong industry backing and a commitment to innovation and market expansion.
Techsomed's BioTrace platform is designed to be hardware-agnostic, integrating seamlessly with standard commercial ultrasound imaging systems and existing ablation devices. This approach aims to facilitate adoption by leveraging current hospital equipment, potentially reducing initial investment costs compared to systems requiring specialized hardware.
By providing real-time visualization and predictive modeling of the ablation zone, Techsomed's technology aims to improve treatment precision and safety, minimizing damage to healthy tissue and maximizing tumor destruction. This enhanced control is intended to lead to higher efficacy, reduced recurrence rates, and improved patient outcomes.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.